Results 181 to 190 of about 6,776,213 (311)

Sustainable Development in the World Environmental Strategy [PDF]

, 2014
Deryabkina, Tatiana, Klimkina, I.I., Kostrytska, S.I.   +2 more
core  

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Temporal dynamics of ferroptosis markers and neuroprotective intervention in cerebral ischemia-reperfusion injury: Insights for therapeutic strategy development. [PDF]

Iran J Basic Med Sci
Bao S, Liu C, Wang QW, Zhang C, Zhao H.
europepmc   +1 more source

Correction to: Building a Children's Health Service and System Research Strategy: development and integration in an Australian paediatric healthcare setting. [PDF]

BMC Health Serv Res, 2020
Littlewood R, Canfell OJ, Tracey F.
europepmc   +1 more source

Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma

Molecular Oncology, EarlyView.
The causes of central nervous system (CNS) hemangioblastoma in Von Hippel–Lindau (vHL) disease are unclear. We used Whole Exome Sequencing (WES) on familial hemangioblastoma to investigate events that underlie tumor development. Our findings suggest that VHL loss creates a permissive environment for tumor formation, while additional alterations ...
Maja Dembic, Anne Nørremølle, Lilian Bomme Ousager, Lars van Brakel Andersen, Marie Louise Mølgaard Binderup, Mads Thomassen   +5 more
wiley   +1 more source

The searchbuildR shiny app: A new implementation of the objective approach for search strategy development in systematic reviews. [PDF]

Cochrane Evid Synth Methods
Kapp C, Fujita-Rohwerder N, Lilienthal J, Sieben W, Waffenschmidt S, Hausner E.   +5 more
europepmc   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Addressing opioid misuse through community-engaged strategy development: study protocol of a randomized controlled trial. [PDF]

Res Involv Engagem
Zimmerman EB, Rafie C, Wenzel SG, Hosig K, Villani D, Dance J, Lee SS.   +6 more
europepmc   +1 more source

Innovative oncology products: time to revisit the strategy development? [PDF]

ESMO Open, 2019
Krendyukov A.
europepmc   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source